These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22089178)

  • 1. Interaction between oral estrogen plus progestogen therapy and ABO blood groups on coagulation activation in postmenopausal women.
    Guimarães DA; dos Santos MS; Gomes KB; van der Bom JG; Rios DR; Cardoso J; Franco RM; Teixeira Gda S; Dusse LM; Carvalho Md; Fernandes AP
    Menopause; 2012 Mar; 19(3):339-45. PubMed ID: 22089178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents.
    Klarmann D; Eggert C; Geisen C; Becker S; Seifried E; Klingebiel T; Kreuz W
    Transfusion; 2010 Jul; 50(7):1571-80. PubMed ID: 20210927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals.
    Schleef M; Strobel E; Dick A; Frank J; Schramm W; Spannagl M
    Br J Haematol; 2005 Jan; 128(1):100-7. PubMed ID: 15606555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABO blood group and von Willebrand factor levels partially explained the incomplete penetrance of congenital thrombophilia.
    Cohen W; Castelli C; Alessi MC; Aillaud MF; Bouvet S; Saut N; Brunet D; Barthet MC; Tregouet DA; Lavigne G; Morange PE
    Arterioscler Thromb Vasc Biol; 2012 Aug; 32(8):2021-8. PubMed ID: 22628432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
    Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L; Favaloro JW
    Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women.
    Ay C; Thom K; Abu-Hamdeh F; Horvath B; Quehenberger P; Male C; Mannhalter C; Pabinger I
    Haemophilia; 2010 Jan; 16(1):111-7. PubMed ID: 19758307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction.
    O'Donnell J; Tuddenham EG; Manning R; Kemball-Cook G; Johnson D; Laffan M
    Thromb Haemost; 1997 May; 77(5):825-8. PubMed ID: 9184386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism.
    Tirado I; Mateo J; Soria JM; Oliver A; Martínez-Sánchez E; Vallvé C; Borrell M; Urrutia T; Fontcuberta J
    Thromb Haemost; 2005 Mar; 93(3):468-74. PubMed ID: 15735796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort.
    Morange PE; Tregouet DA; Frere C; Saut N; Pellegrina L; Alessi MC; Visvikis S; Tiret L; Juhan-Vague I
    Br J Haematol; 2005 Jan; 128(1):91-9. PubMed ID: 15606554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens.
    Morelli VM; de Visser MC; van Tilburg NH; Vos HL; Eikenboom JC; Rosendaal FR; Bertina RM
    Thromb Haemost; 2007 Apr; 97(4):534-41. PubMed ID: 17393014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is breast cancer risk the same for all progestogens?
    Stute P
    Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between circulating tumor necrosis factor system and bone mass before and after estrogen plus progestogen therapy.
    Kim JG; Ku SY; Kim H; Chun SW; Suh CS; Choi YM
    Menopause; 2009; 16(3):534-8. PubMed ID: 19225428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms.
    Albánez S; Ogiwara K; Michels A; Hopman W; Grabell J; James P; Lillicrap D
    J Thromb Haemost; 2016 May; 14(5):953-63. PubMed ID: 26875505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
    Winkler UH; Krämer R; Kwee B; Schindler AE
    Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thrombophilic syndrome associated to phenotypic resistance to activated protein C in postmenopausal women].
    Caserta L; Caserta R; Torella M; Perricone F; Nesti E; Sessa M; Tagliaferri A; De Francesco F; De Lucia D; Panariello S
    Minerva Ginecol; 2004 Apr; 56(2):131-6. PubMed ID: 15258541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
    Cosman F; Baz-Hecht M; Cushman M; Vardy MD; Cruz JD; Nieves JW; Zion M; Lindsay R
    Thromb Res; 2005; 116(1):1-13. PubMed ID: 15850603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABO blood group, hypercoagulability, and cardiovascular and cancer risk.
    Franchini M; Favaloro EJ; Targher G; Lippi G
    Crit Rev Clin Lab Sci; 2012; 49(4):137-49. PubMed ID: 22856614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
    Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
    Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
    Połać I; Borowiecka M; Wilamowska A; Nowak P
    Gynecol Endocrinol; 2013 Feb; 29(2):165-8. PubMed ID: 23116237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.